Prevention, Diagnosis, and Treatment of Acute Altitude Illness
Date Added:
October 28, 2024
Journal/Publication:
JAMA
Publisher:
American Medical Association
Publication Date:
October 24, 2024
Type:
Meta-analyses, Reviews, and Guidelines
Format:
Article
DOI (1):
10.1001/jama.2024.19562
PMID (1):
39446318
Abstract
People traveling to high altitude are at risk of developing acute altitude illnesses, including AMS, HACE, and HAPE. Incidence and risk are assessed by history of acute altitude illness, sleeping elevation above sea level on day 1 of travel, and rate of ascent. AMS incidence can range from approximately 3% in persons traveling to 2000 m (6561 ft) to 25% to 40% at altitudes above 4300 m (14 107 ft), with symptoms varying from mild to marked.3 While rare, HACE and HAPE are potentially life-threatening if untreated.
Text Availability
Free full text
RPR Commentary
A summary of recommended measures to prevent and treat altitude sickness. James W. Mold, MD, MPH